– FRANCE, Lyon – MaaT Pharma (EPA: MAAT), a clinical-stage biotechnology company, today announced the appointments of Dr. Karim Dabbagh (Ph.D.) and Dr. Nadia Kamal (Ph.D.) to its Board as Independent Directors.
Dr. Karim Dabbagh has been appointed as Board Chairman, succeeding Jean-Marie Lefèvre, who will continue to serve as a Board member.
Dr. Kamal will join the ESG committee as its chair.
Dr. Karim Dabbagh
About Dr. Karim Dabbagh
Based in the U.S., Dr. Dabbagh, president and CEO of Second Genome Inc., is renowned for his innovative work in microbiome science. As a former executive at Pfizer and Roche, he brings extensive experience in pharmaceutical development.
Dr. Karim Dabbagh said, “I am thrilled to join one of the companies at the forefront of the global microbiome field. The groundbreaking advancements and pioneering research undertaken by MaaT Pharma have truly set them apart. I look forward to contributing to their continued success as we strive to make a lasting impact on the future of microbiome innovation for patients while delivering value to our shareholders.”
About Dr. Nadia Kamal
Dr. Nadia Kamal is the Director of the Technology, Health, and Innovation Divisions at Harmonie Mutuelle. She has a wealth of experience in Corporate Social Responsibility and a strong background in serving patients and fostering innovation.
About MaaT Pharma
MaaT Pharma, a clinical-stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, an open-label, single-arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice.
Source: https://www.maatpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.